If we know that MAC-associated cavitary lung disease is a marker of poor outcomes and/or refractory disease at the time of initial presentation, what is the rationale for waiting before deploying the amikacin liposome inhalation suspension?

If we know that MAC-associated cavitary lung disease is a marker of poor outcomes and/or refractory disease at the time of initial presentation, what is the rationale for waiting before deploying the amikacin liposome inhalation suspension?

CLICK HERE FOR CME CREDIT

If we know that MAC-associated cavitary lung disease is a marker of poor outcomes and/or refractory disease at the time of initial presentation, what is the rationale for waiting before deploying the amikacin liposome inhalation suspension?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Patrick Flume, MD

Patrick Flume, MD

Professor of Medicine and Pediatrics
Medical University of South Carolina
Powers-Huggins Endowed Chair for Cystic Fibrosis
University of South Carolina
Charleston, South Carolina